Data from an observational study
Data on mid-life or older patients with MS derive from a post-hoc analysis of an observational study cohort . Participating patients started Betaferon treatment within the 6 months prior to study entry. The effectiveness and safety of Betaferon in middle-aged patients (aged 41 to 50 years, n=327) and older patients (> 50 years, n=154) was evaluated. In both age groups, the annualized relapse rate decreased considerably from the pre-study to the study period treatment (see figure). Over the course of the study, relapses and disease progression, as well as anxiety and depression scores (as measured by HADs), were similar and stable in the two age groups. Polypharmacy (five or more medications) was seen in 32.3 and 41.2 % of patients aged 41–50 and > 50 years respectively. No unexpected adverse events were reported. Findings suggest that Betaferon can be an effective and well-tolerated treatment option in MS patients of advanced age.
Annualized relapse rate, mean (SD), in middle-age or older patients before and during the observational study . Study participants started Betaferon treatment within the 6 months prior to study entry.
HADS, Hospital Anxiety and Depression Scale
SD, standard deviation
- Patti F et al. BMC Neurol 2021; 21(1): 324. Return to content